JY Lee, HJ Kim… - Annals of Neurology, 2011 - Wiley Online Library Page 1. Is pathological gambling in Parkinson's disease reduced by amantadine? ... treatment strategies remain very challenging. Thomas et al.3 recently showed that PG can be reduced by amantadine administration in arandomized ... Cited by 2 - Related articles - All 2 versions
RA Bosnell, R Mitchell, D Siddique… - Journal of Neurology, …, 2011 - jnnp.bmj.com OMAS is rare affecting 1 in 10 million people per year. Symptoms include rapid, involuntary, multidirectional conjugate eye move- ments, brief involuntary movements of muscles and truncal/ appendicular cerebellar ataxia. The combination of its rarity and postulated ...
B Ossola, N Schendzielorz, SH Chen, GS Bird… - …, 2011 - Elsevier Amantadine is commonly given to alleviate L-DOPA-induced dyskinesia of Parkinson's disease (PD) patients. Animal and human evidence showed that amantadine may also exert neuroprotection in several neurological disorders. Additionally, it is generally believed that this ... All 2 versions
VP Hoffmann, M Case… - The Journal of clinical …, 2011 - ncbi.nlm.nih.gov OBJECTIVE: This 22-week, open-label study, conducted between November 2006 and September 2008 in a community setting, was designed to determine if weight gain during olanzapine treatment can be prevented or mitigated with adjunctive treatment algorithms that include ...
A Salter, B Ni Laoi… - Intervirology, 2011 - content.karger.com Objectives: To determine the prevalence of amantadine-resistant influenza A viruses and perform genetic analysis of isolates collected in Dublin during six seasons (2003/2004 to 2008/2009). Methods: Known mutations in the matrix 2 gene (M2) conferring amantadine ... Related articles - All 2 versions
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
